Klaus R. Dr Veitinger is Director at INTERCEPT PHARMACEUTICALS INC (ICPT). They have made 15 open-market trades across 1 company since 2013, most recently 2021-06-10.
CIK 0001283972
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TCDA | SELL | 2019-11-01 | 2019-11-05 | $38.87 | $68K | -14.3% | +2.2% | -4.9% |
| TCDA | SELL | 2019-11-01 | 2019-11-05 | $38.88 | $136K | -14.3% | +2.2% | -4.9% |
| TCDA | SELL | 2019-10-25 | 2019-10-29 | $36.30 | $191K | +5.5% | +8.1% | -10.8% |
| TCDA | SELL | 2019-10-25 | 2019-10-29 | $36.30 | $191K | +5.5% | +8.1% | -10.8% |
| TCDA | SELL | 2019-09-26 | 2019-09-30 | $31.42 | $132K | -0.3% | +21.1% | +23.0% |
| TCDA | SELL | 2019-08-26 | 2019-08-28 | $33.16 | $139K | -4.6% | -11.2% | +14.9% |
| TCDA | SELL | 2019-07-25 | 2019-07-29 | $31.62 | $133K | +4.4% | +10.6% | +19.9% |
| TCDA | SELL | 2019-07-05 | 2019-07-09 | $36.30 | $127K | -3.2% | -5.9% | -9.6% |
| TCDA | SELL | 2019-07-03 | 2019-07-05 | $36.90 | $336K | -5.3% | -16.0% | -9.6% |
| TCDA | SELL | 2019-07-03 | 2019-07-05 | $36.90 | $336K | -5.3% | -16.0% | -9.6% |
| TCDA | SELL | 2019-03-28 | 2019-03-29 | $34.19 | $1.5M | -14.2% | -14.2% | -3.9% |
| TCDA | SELL | 2019-03-26 | 2019-03-28 | $23.83 | $286K | -5.3% | -6.5% | -4.0% |
| TCDA | SELL | 2019-02-25 | 2019-02-27 | $22.60 | $181K | +2.2% | +67.9% | +60.2% |
| TCDA | SELL · 10b5-1 | 2019-01-28 | 2019-01-30 | $20.31 | $122K | +7.0% | +14.7% | +65.7% |
| TCDA | SELL | 2019-01-25 | 2019-01-28 | $20.86 | $125K | +4.2% | +14.4% | +69.7% |
| TCDA | SELL · 10b5-1 | 2018-12-27 | 2018-12-31 | $23.71 | $58K | +0.3% | -10.8% | +52.4% |
| TCDA | SELL | 2018-12-26 | 2018-12-28 | $24.97 | $408K | -2.6% | -14.9% | +60.4% |
| ICPT | SELL · 10b5-1 | 2015-11-10 | 2015-11-12 | $198.25 | $198K | -17.1% | +1.2% | -34.5% |
| ICPT | SELL · 10b5-1 | 2015-09-09 | 2015-09-11 | $198.25 | $99K | -17.1% | +1.2% | +1.2% |
| ICPT | SELL · 10b5-1 | 2015-08-03 | 2015-08-05 | $261.17 | $131K | -17.1% | +1.2% | +1.2% |
| ICPT | SELL · 10b5-1 | 2015-06-10 | 2015-06-12 | $238.21 | $93K | -17.1% | +1.2% | +1.2% |
| ICPT | SELL · 10b5-1 | 2015-05-11 | 2015-05-13 | $279.07 | $109K | -17.1% | +1.2% | +1.2% |
| RLYP | SELL · 10b5-1 | 2015-05-11 | 2015-05-13 | $36.06 | $210K | -30.6% | +0.6% | +0.6% |
| RLYP | SELL · 10b5-1 | 2015-04-10 | 2015-04-13 | $35.35 | $206K | -30.6% | +0.6% | +0.6% |
| ICPT | SELL · 10b5-1 | 2015-04-10 | 2015-04-14 | $272.10 | $106K | -17.1% | +1.2% | +1.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.